Joël has more than 30 years of experience in the Biotech and the Pharma industry. He has been the cofounder and CEO of InnaVirVax, a French biotech that developed a candidate therapy for HIV infection up to phase 2 clinical trial. Joël has had various positions in several biotech companies (Genetica, AP cells, Neurotech and Alfact Innovation) and in the Pharma (Rhone-Poulenc Rorer now part of Sanofi Aventis) and has been involved actively in 5 different drug candidates studied in the clinic, up to phase 3. Scientific by training, Joël is a co-author of more than 60 peer reviewed publications and 30 patent families in various therapeutic fields.
Joël is graduated from AgroParisTech and holds a PhD from Université de Paris.